Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of “Moderate Buy” by Brokerages

Rezolute, Inc. (NASDAQ:RZLT) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $9.3750.

Several equities analysts have issued reports on RZLT shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Rezolute in a research note on Tuesday, June 2nd. Maxim Group lifted their target price on Rezolute from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. BTIG Research lifted their target price on Rezolute from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Citizens Jmp upgraded Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price on the stock in a research note on Wednesday, June 3rd. Finally, Guggenheim lifted their target price on Rezolute from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, June 15th.

Hedge Funds Weigh In On Rezolute

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in Rezolute by 5.0% in the third quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company’s stock valued at $312,000 after purchasing an additional 1,567 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Rezolute by 5.5% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company’s stock worth $363,000 after acquiring an additional 2,014 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Rezolute by 8.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 45,088 shares of the company’s stock worth $107,000 after acquiring an additional 3,630 shares during the last quarter. AlphaCentric Advisors LLC grew its stake in shares of Rezolute by 6.2% during the first quarter. AlphaCentric Advisors LLC now owns 71,227 shares of the company’s stock worth $217,000 after acquiring an additional 4,171 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Rezolute during the second quarter worth about $25,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Price Performance

RZLT stock opened at $5.10 on Tuesday. The business has a 50-day moving average price of $3.78 and a 200 day moving average price of $3.27. The company has a market capitalization of $491.08 million, a P/E ratio of -6.22 and a beta of 0.68. Rezolute has a 1-year low of $1.07 and a 1-year high of $11.46.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. On average, analysts anticipate that Rezolute will post -0.69 earnings per share for the current fiscal year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.